Skip to content

Efficacy and safety of acromial slide capsule block in enhanced extracorporeal shock wave treatment of adhesive shoulder capsultis

Efficacy and safety of acromial slide capsule block in enhanced extracorporeal shock wave treatment of adhesive shoulder capsultis

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400081020
Enrollment
Unknown
Registered
2024-02-20
Start date
2024-02-27
Completion date
Unknown
Last updated
2024-02-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

adhesive shoulder capsultis

Interventions

Experimental group:Subacromial sac block combined with extracorporeal shock wave therapy
Control group:Placebo injection + extracorporeal shock wave therapy

Sponsors

The First Affiliated Hospital of the Air Force Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1) Patients diagnosed with adhesive shoulder capsitis; 2) Duration of disease: 1 to 12 months; 3) Age =18 years old; 4) The mobility of the shoulder joint is limited in 2 or more directions =30°; 5) Agree to participate in the study and sign the informed consent.

Exclusion criteria

Exclusion criteria: 1) Patients with other diseases: such as infectious diseases, joint trauma, calcifying supraspinatus tendinitis, rotator cuff injury, neoplastic lesions, etc. 2) Severe cardiopulmonary insufficiency, severe liver and kidney insufficiency and combined with blood system diseases; 3) Patients who are not suitable for extracorporeal shock wave therapy and hormone injection therapy: such as coagulation dysfunction, installation of cardiac pacemaker or unstable angina pectoris, congestive heart failure, pregnant women, sensory dysfunction, peripheral neuropathy, diabetes and poor blood glucose control (fasting blood glucose =10.0mmol/L); 4) Patients who have received local injection treatment around the shoulder in the past 4 weeks; 5) Patients who are allergic to local anesthetics, hormones and other drugs used in this study; 6) Patients requiring surgery or recent immunization at the treatment site; 7) Those who have mental illness or cognitive dysfunction can not fully understand the research scale.

Design outcomes

Primary

MeasureTime frame
Degree of improvement in shoulder joint function;

Secondary

MeasureTime frame
Visual analogue pain score;Oxford Shoulder Joint Score Questionnair;Reduce Constant-Murley score;cure rate;effective rate;improvement rate;Remedial medication;

Countries

China

Contacts

Public ContactGu Nan

The First Affiliated Hospital of the Air Force Medical University

1760407214@qq.com+86 139 9129 2113

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026